60 Degrees Pharmaceuticals Inc. SXTP
- Market cap
- $4.1M
- P/E
- 0.0×
Follow SXTP
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 122.64 | 14.04 | 1.80 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 2,076.00 | 271.20 | 32.00 |
High Price
|
|||
| — | — | — | — | — | — | 2 | 3 | 3 | 3 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 3 | 6 | 1 | 0 | 1 | 1 |
Revenue
|
|||
| — | — | — | — | 72.43% | 86.61% | 15.41% | (87.15%) | 43.53% | 44.52% |
Gross Margin
|
|||
| — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) |
EBT
|
|||
| — | — | — | — | (119.53%) | (67.04%) | (1,208.39%) | (1,503.79%) | (1,167.72%) | (522.91%) |
EBT Margin
|
|||
| — | — | — | — | (3) | (4) | (6) | (4) | (8) | (7) |
Net Income
|
|||
| — | — | — | — | 0 | 1 | 1 | 2 | 4 | 0 |
Depreciation
|
|||
| — | — | — | — | 0.44 | 1.10 | 51.64 | 15.37 | 5.98 | 2.10 |
Revenue/Sh
|
|||
| — | — | — | — | (0.52) | (0.74) | (626.38) | (237.69) | (74.20) | (11.73) |
Earnings/Sh
|
|||
| — | — | — | — | (0.03) | (0.11) | (102.02) | (275.33) | (49.54) | (10.22) |
Cash Flow/Sh
|
|||
| — | — | — | — | 0.00 | (0.01) | (6.08) | (7.02) | (1.59) | (0.33) |
Capex/Sh
|
|||
| — | — | — | — | (0.03) | (0.12) | (108.10) | (282.35) | (51.13) | (10.55) |
Free CF/Sh
|
|||
| — | — | — | — | (3.03) | (3.14) | (2,439.30) | 290.79 | 34.69 | 5.04 |
Book Value/Sh
|
|||
| — | — | — | — | 6 | 6 | 0 | 0 | 0 | 1 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 25.28 | 25.28 | 25.28 | 16.08 | 4.32 | 0.97 |
PS Ratio
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| — | — | — | — | 28.01 | 28.01 | 28.01 | 8.24 | (0.43) | (0.88) |
EV/Sales
|
|||
| — | — | — | — | (10.76) | (10.76) | (10.76) | (0.45) | 0.05 | 0.18 |
EV/FCF
|
|||
| — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) |
Op' Cash Flow
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | 0 | (1) | (1) | (5) | (6) | (7) |
FCF
|
|||
| — | — | — | — | 1 | 1 | (23) | 4 | 4 | 3 |
Working Cap'
|
|||
| — | — | — | — | 19 | 19 | 5 | — | — | — |
Total Debt
|
|||
| — | — | — | — | 19 | 19 | 5 | (2) | (3) | (3) |
Net Debt
|
|||
| — | — | — | — | (18) | (18) | (24) | 5 | 4 | 3 |
Sh' Equity
|
|||
| — | — | — | — | 0.00% | (212.61%) | (459.49%) | (82.94%) | (117.36%) | (132.40%) |
ROA
|
|||
| — | — | — | — | 0.00% | (171.52%) | 0.00% | (121.31%) | (1,070.52%) | (771.42%) |
ROIC
|
|||
| — | — | — | — | 0.00% | 23.85% | 29.23% | 25.78% | 148.93% | 124.83% |
ROE
|
|||
60 Degrees Pharmaceuticals Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OSRH OSR Health, Inc. | $4.1M | 0.0× | Compare |
| MBIO Mustang Bio, Inc. | $4.0M | 0.0× | Compare |
| HCWB HCW Biologics Inc. | $4.2M | 0.0× | Compare |
| VIVS VivoSim Labs, Inc. | $3.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MLEC Moolec Science SA | $4.3M | 0.0× | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $4.3M | 0.0× | Compare |
| JAGX Jaguar Animal Health, Inc. | $3.8M | 0.1× | Compare |
| JUNS Jupiter Neurosciences, Inc. | $3.8M | 0.0× | Compare |
60 Degrees Pharmaceuticals Inc. (SXTP) key facts
- 60 Degrees Pharmaceuticals Inc. (SXTP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- 60 Degrees Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 106.8% from fiscal 2024.
- As of September 25, 2026, SXTP traded at $1.17, a market capitalization of $4.1 million.
- Return on equity was 124.8% and debt-to-equity 0.00.
60 Degrees Pharmaceuticals Inc. (SXTP) Latest News
14 Aug
60 Degrees Pharmaceuticals Inc. (SXTP) announced its second quarter 2026 financial results. Quarterly earnings reports influence market sentiment regarding operational and financial status.
30 Jul
60 Degrees Pharmaceuticals Inc. (SXTP) announced a private placement priced at-the-market under Nasdaq rules. Private placement supplies operating capital but risks share dilution and short-term price pressure.
8 Jul
60 Degrees Pharmaceuticals Inc. (SXTP) secured an exclusive option agreement with Florida State University to advance castanospermine for tick-borne diseases. Exclusive option agreement expands SXTP pipeline directly in its core tick-borne disease focus area.
1 Jul
60 Degrees Pharmaceuticals receives positive Data Safety Monitoring Board recommendation for B-FREE Phase 2 study of tafenoquine in chronic Babesiosis patients with severe fatigue. Positive DSMB recommendation advances tafenoquine Phase 2 trial continuation and strengthens pipeline prospects.
11 Jun
60 Degrees Pharmaceuticals Inc. signed an exclusive patent license agreement with Florida State University for non-prescription use of Australian Chestnut Extract as a botanical supplement. Exclusive license adds a new botanical supplement product line with potential to expand revenue streams.
26 May
60 Degrees Pharmaceuticals enrolls first seasonal patient early in tafenoquine babesiosis trial. Early enrollment marks pipeline progress but remains early-stage without immediate revenue or approval impact.
15 May
60 Degrees Pharmaceuticals Inc. (SXTP) announced first quarter 2026 results. Quarterly financial results directly affect investor sentiment and stock performance.
15 Apr
60 Degrees Pharmaceuticals Inc. (SXTP) announces ARAKODA (tafenoquine) for malaria prevention is now available on the Runway Health travel website. ARAKODA availability on Runway Health expands distribution to travelers, potentially boosting sales and market reach moderately.
3 Apr
60 Degrees Pharmaceuticals Inc. (SXTP) upgraded to Buy rating by analysts, providing key insights for investors on the company's prospects. Analyst upgrade to Buy signals moderately positive shift in investor sentiment, potentially impacting SXTP's stock price and market positioning.
31 Mar
60 Degrees Pharmaceuticals Inc. (SXTP) announced its 2025 annual results. Annual results announcements deliver key financial metrics that significantly shape investor sentiment and company trajectory.
18 Mar
60 Degrees Pharmaceuticals Inc. (SXTP) filed a New Dietary Ingredient Notification (NDIN) with the FDA for Australian Chestnut Extract, advancing potential development and commercialization of a novel dietary supplement ingredient. NDIN filing represents a moderate step in product innovation for dietary supplements, potentially enhancing pipeline and market positioning without guaranteed approval.
11 Mar
60 Degrees Pharmaceuticals Inc. (SXTP) announced all patients cured of babesiosis in an expanded use clinical trial after treatment with tafenoquine. 100% cure rate in babesiosis trial demonstrates tafenoquine's efficacy, potentially transforming SXTP's pipeline and driving explosive stock growth.
24 Feb
60 Degrees Pharmaceuticals Inc. (SXTP) partners with GoodRx to expand access to ARAKODA, its malaria prevention drug, via GoodRx's prescription savings platform. Partnership with GoodRx broadens ARAKODA access, driving potential sales growth and positive market sentiment for SXTP.
7 Feb
GoodRx is reportedly utilizing discounts from ARAKODA to reshape its preventive care strategy, potentially impacting its market positioning and competitive landscape. This move may signify a shift in how the company approaches preventive healthcare services, leveraging cost-effective solutions to attract more users and redefine its service offerings. The strategic shift in preventive care could moderately influence GoodRx's competitive positioning and market sentiment.
2 Feb
60 Degrees Pharmaceuticals Inc. has partnered with GoodRx to enhance access to its malaria treatment, ARAKODA®. This collaboration aims to provide patients with more affordable options for the medication, which is crucial for those at risk of malaria. The partnership is expected to improve patient adherence and overall health outcomes by leveraging GoodRx's platform to offer discounts and savings on prescriptions. The partnership with GoodRx is a significant strategic move that could enhance market access and patient adherence for ARAKODA®, impacting future performance.
28 Jan
60 Degrees Pharmaceuticals Inc. has exercised its license option with Florida State University to pursue large-scale purification of castanospermine for non-prescription use. This move aims to enhance the company's capabilities in producing this compound, which has potential applications in various markets beyond pharmaceuticals. The licensing agreement represents a significant strategic move that could enhance production capabilities and market opportunities for the company.
22 Jan
60 Degrees Pharmaceuticals Inc. has partnered with Runway Health to offer international travelers direct access to ARAKODA®, a medication for malaria prevention. This collaboration aims to enhance accessibility for travelers at risk of malaria, particularly in endemic regions, thereby promoting health and safety during their journeys. The partnership significantly enhances the distribution and accessibility of ARAKODA®, potentially impacting market reach and revenue growth.
60 Degrees Pharmaceuticals Inc. (SXTP) has been identified as one of the top midday gainers in the stock market, reflecting a positive shift in investor sentiment and market performance. The company's stock has shown significant upward movement, indicating potential interest from investors and analysts alike. This surge may be attributed to recent developments or market trends favoring the pharmaceutical sector, positioning SXTP favorably among its peers. The stock's midday gain suggests a moderately noticeable influence on market sentiment and potential financial performance.
15 Jan
60 Degrees Pharmaceuticals, Inc. has announced the approval of a reverse stock split ratio, which is aimed at increasing the per-share price of its common stock. This decision is part of the company's strategy to meet the minimum bid price requirement for continued listing on the Nasdaq. The reverse split will affect all outstanding shares and is expected to be effective on a date to be determined by the company’s board of directors. The reverse stock split may influence market perception and stock price stability, but its overall impact on the company's long-term trajectory is expected to be limited.
29 Dec
60 Degrees Pharmaceuticals Inc. (SXTP) reported that a peer-reviewed study at NC State found Babesia infection in 24% of patients presenting with chronic fatigue. This finding highlights a potential link between chronic fatigue and Babesia, suggesting further investigation into treatment options may be warranted. The detection of Babesia infection in a significant portion of chronic fatigue patients could lead to strategic shifts in research and product development.
26 Dec
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Inc. (SXTP) are set to be featured in interviews on the RedChip Small Stocks, Big Money(TM) Show, airing on Bloomberg TV. This exposure aims to highlight their business strategies and growth potential to a broader audience, potentially attracting investor interest. Increased visibility through media exposure may positively influence market sentiment and investor interest.
23 Dec
60 Degrees Pharmaceuticals Inc. (SXTP) is being highlighted as a potential investment opportunity due to its recent stock price decline, which may present a buying opportunity for investors. The company is focusing on developing innovative therapies, and analysts suggest that its current valuation may not reflect its future growth potential. Market conditions and investor sentiment are also considered, indicating that SXTP could be positioned for recovery as it advances its product pipeline and addresses market challenges. The company's focus on innovative therapies and potential recovery in stock price suggests a moderately noticeable influence on its future performance.
11 Dec
60 Degrees Pharmaceuticals Inc. announced plans to expand the sales and marketing of its product ARAKODA® in 2026, aiming to enhance its market presence and reach more patients. This strategic move is expected to bolster the company's growth and improve its competitive positioning in the pharmaceutical market. The expansion of ARAKODA® sales and marketing is a significant strategic move that could enhance the company's market position and investor sentiment.
21 Nov
60 Degrees Pharmaceuticals Inc. announced that the clinical site for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine is now open for patient enrollment. This study aims to evaluate the safety and efficacy of a treatment for chronic babesiosis, a tick-borne disease. The opening of the site marks a significant step in advancing the clinical trial process. The initiation of patient enrollment for a clinical study may moderately influence the company's future performance and market sentiment.
13 Nov
60 Degrees Pharmaceuticals Inc. (SXTP) reported its third quarter 2025 financial results, highlighting key metrics such as revenue growth, expenses, and strategic initiatives. The company continues to focus on expanding its product pipeline and enhancing operational efficiency. Management expressed optimism about future prospects and ongoing projects aimed at improving market position. The financial results indicate moderate growth and strategic initiatives that may influence the company's competitive positioning.
31 Oct
60 Degrees Pharmaceuticals Inc. (SXTP) and NDT Pharmaceuticals will be featured in interviews on the RedChip Small Stocks, Big Money(TM) Show airing on Bloomberg TV. This exposure aims to highlight their business strategies and growth potential to a broader audience, potentially attracting investor interest. Increased visibility through media exposure may positively influence market sentiment and investor interest.
15 Oct
60 Degrees Pharmaceuticals Inc. announced that the first patient in their relapsing babesiosis study showed no detection of Babesia infection following treatment with Tafenoquine. This marks a significant milestone in their research efforts against the disease. Successful treatment outcomes in clinical studies can significantly enhance the company's market position and investor confidence.
9 Oct
60 Degrees Pharmaceuticals Inc. has announced the name of its clinical trial for chronic babesiosis, called the B-FREE Chronic Babesiosis Study. This trial aims to evaluate the efficacy and safety of the company's treatment for this tick-borne disease, which can lead to severe health complications. The study's initiation marks a significant step in addressing an unmet medical need in the treatment of chronic babesiosis. The launch of the B-FREE study represents a significant strategic move that could enhance the company's product pipeline and market position in a niche therapeutic area.
19 Sep
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Inc. (SXTP) are set to be featured in interviews on the RedChip Small Stocks, Big Money(TM) show airing on Bloomberg TV. This exposure aims to highlight their business developments and growth potential to a broader audience, potentially attracting investor interest. Increased visibility through media exposure may positively influence market sentiment and investor interest.
3 Sep
60 Degrees Pharmaceuticals Inc. (SXTP) announced a new date for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference and provided a link for a live webcast of the event. This presentation is expected to highlight the company's developments and strategic direction. The presentation may influence investor sentiment and provide insights into the company's future plans.